Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
Editor’s note: This is a developing news story. Please check back soon for updates.
At 12 months in a phase 1/2 trial, the Bimatoprost Drug Pad-IOL System improved IOP, vision and treatment burden in patients with open-angle glaucoma or ocular hypertension with concomitant cataract.
According to a press release from SpyGlass Pharma, 104 patients were randomly assigned 2:1:1 to receive 78 µg Bimatoprost Drug Pad-IOL System (BIM-IOL System) (51 patients) with daily administration of artificial tear drops, 39 µg BIM-IOL System (23 patients) with daily administration of artificial tear drops, or